PMID- 29569659
OWN - NLM
STAT- MEDLINE
DCOM- 20190508
LR  - 20190508
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 54
IP  - 1
DP  - 2018 Jan
TI  - Controversies regarding the cardiovascular effects of testosterone replacement 
      therapy in older men.
PG  - 25-34
LID - 10.1358/dot.2018.54.1.2737935 [doi]
AB  - Testosterone (T) levels decline with the advancement of age and have been 
      associated with increased incidence of cardiovascular disease (CVD). Indeed, 
      several epidemiologic and prospective cohort studies have suggested that low T 
      levels (lower tertile or quartile) are associated with increased incidence of 
      CVD, type 2 diabetes mellitus (T2DM), obesity and dyslipidemia. In contrast, 
      correction of low T levels with testosterone replacement therapy (TRT) is 
      associated with a decrease in the incidence of CVD, T2DM and dyslipidemia as has 
      been demonstrated by several randomized, controlled trials as well as prospective 
      cohort studies. However, recent studies have shown that TRT is associated with an 
      increased incidence of adverse CV events and these studies have created a great 
      controversy regarding the CV benefits of TRT. In order to get a better 
      perspective on the current status of TRT, a focused MEDLINE and Cochrane database 
      search of the recent English language literature between 2010 and 2017 was 
      conducted and 29 pertinent papers were retrieved. The studies reviewed could not 
      definitely confirm the beneficial or adverse CV effects of TRT. Therefore, on the 
      basis of the current stage of knowledge, older male subjects with low T levels 
      could continue to receive TRT, but this decision should be discussed with their 
      physicians.
CI  - Copyright 2018 Clarivate Analytics.
FAU - Chrysant, S G
AU  - Chrysant SG
AD  - University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. 
      schrysant@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Cardiovascular Diseases/*epidemiology
MH  - Diabetes Mellitus, Type 2/epidemiology
MH  - Dyslipidemias/epidemiology
MH  - *Hormone Replacement Therapy/adverse effects
MH  - Humans
MH  - Male
MH  - Obesity/epidemiology
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Testosterone/*adverse effects/*therapeutic use
OTO - NOTNLM
OT  - Cardiovascular events
OT  - Low testosterone levels
OT  - Testosterone replacement therapy
EDAT- 2018/03/24 06:00
MHDA- 2019/05/09 06:00
CRDT- 2018/03/24 06:00
PHST- 2018/03/24 06:00 [entrez]
PHST- 2018/03/24 06:00 [pubmed]
PHST- 2019/05/09 06:00 [medline]
AID - 2737935 [pii]
AID - 10.1358/dot.2018.54.1.2737935 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2018 Jan;54(1):25-34. doi: 10.1358/dot.2018.54.1.2737935.